Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2013 | 10:15am CET

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:
www.drreddys.com

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com/ +91-40-66834297
Saunak Savla at saunaks@drreddys.com/ +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com/ +1 908-203-4931

Media:
S Rajan at rajans@drreddys.com/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DR.REDDY'S LABORATORIES LT
12/05 IMS HEALTH : Dr. Reddy Lab launches Nystatin and Triamcinolone Acetonide Cream, ..
12/05 DR REDDY LABORATORIES : announces the launch of Nystatin and Triamcinolone Aceto..
11/25 DR REDDY LABORATORIES : CENTRE APPROVES FOUR FDI PROPOSALS WORTH Rs93 CRORE
11/23 MONOCLONAL ANTIBODIES MARKET 2016-20 : Celltrion, Boehringer Ingelheim, Dr Reddy..
11/22 C4X Discovery Holdings plc Strengthens Board with Two Senior Appointments
11/14 DR.REDDY'S LABORATORIES LTD : Blog Coverage Dr. Reddy's Labs Launches Generic Os..
11/12 DR REDDY LABORATORIES : Launches osteoporosis drug in us
11/11 DR REDDY LABORATORIES : Announces the Launch of Raloxifene HCl Tablets, USP in t..
11/07 DR REDDY LABORATORIES : Govt. clears fdi proposals
10/28 DR REDDY LABORATORIES : FIPB clears 7 FDI proposals worth Rs 100 crore
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/05 Dr. Reddy's launches generic topical creams in U.S.
12/01 Vantage Point - Going Small To Hit It Big
11/18 MOMENTA : Short-Term Catalysts Ready To Change The Long-Term Valuation
11/11 Dr. Reddy's launches generic version of Evista in U.S.
10/28 Indian Pharma Names May Come Under Stress
Advertisement
Financials ( INR)
Sales 2017 148 645 M
EBIT 2017 17 858 M
Net income 2017 16 140 M
Debt 2017 12 642 M
Yield 2017 0,58%
P/E ratio 2017 33,53
P/E ratio 2018 21,88
EV / Sales 2017 3,74x
EV / Sales 2018 3,19x
Capitalization 542 978 M
More Financials
Chart DR.REDDY'S LABORATORIES LT
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Full-screen chart
Technical analysis trends DR.REDDY'S LABORA...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 44
Average target price 3 166  INR
Spread / Average Target -0,46%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DR.REDDY'S LABORATORIE..2.38%7 981
JOHNSON & JOHNSON8.98%304 591
PFIZER INC.-2.14%191 942
ROCHE HOLDING LTD.-19.65%188 878
NOVARTIS AG-20.79%178 737
MERCK & CO., INC.15.73%168 544
More Results